Concord Biotech Limited has reported strong Q1 FY27 results, showcasing remarkable growth with standalone revenue up 27.71% YoY to ₹260.52 crore and net profit soaring 43.74% YoY to ₹61.19 crore. This performance reflects a notable recovery from a challenging previous fiscal year. Key developments include securing USFDA approval for Tofacitinib Tablets, enabling access to a $500 million market, and successfully passing inspections from Brazil, Kenya, and Uganda, which bolsters export potential. The company’s strategic focus on high-margin formulations and expanding export footprint positions it for sustained earnings growth amid favorable market conditions. Overall, the strong operational momentum has led to a bullish market outlook.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.sahi.com/news/concord-biotech-q1-standalone-revenue-touches-2-6-billion-net-profit-at-612-million-4794-PE1_COR
